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Koen van Besien, Wendy Stock, Elizabeth Rich, Olatoyosi Odenike,
Lucy A. Godley, Peter H. O’Donnell, Justin Kline, Vu Nguyen,
Paula del Cerro, Richard A. Larson, Andrew S. ArtzWe conducted a phase I-II study of transplantation conditioning with clofarabine-melphalan-alemtuzumab for
patients with advanced hematologic malignancies. Ten patients were accrued to the phase I portion, which uti-
lized an accelerated titration design. No dose-limiting toxicity was observed, and clofarabine 40 mg/m2  5,
melphalan 140 mg/m2 1, and alemtuzumab 20 mg 5 was adopted for the phase II study, which accrued 72
patients. Median agewas 54 years. There were 44 patients with acute myelogenous leukemia or myelodysplas-
tic syndromes, 27 with non-Hodgkin lymphoma, and nine patients with other hematologic malignancies. The
largest subgroup of 35 patients had American Society for Blood and Marrow Transplantation high-risk, active
disease. All evaluable patients engrafted with a median time to neutrophil and platelet recovery of 10 and 18
days, respectively. The cumulative incidence of treatment-related mortality was 26% at 1 year. Cumulative in-
cidence of relapsewas 29%at 1 year.Overall survival was 80% (95% confidence interval [CI], 71-89) at 100 days
and 59% (95% CI, 47-71) at 1 year. Progression-free-survival was 45% (95% CI, 33-67) at 1 year. Rapid-onset
renal failure was the main toxicity in the phase II study and more frequent in older patients and those with
baseline decrease in glomerular filtration rate. Grade 3-5 renal toxicity was observed in 16 of 74 patients
(21%) treated at the phase II doses. Clofarabine-melphalan-alemtuzumab conditioning yields promising re-
sponse and duration of response, but renal toxicity poses a considerable risk particularly in older patients.
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Considerable effort has been devoted to the devel-
opment of reduced-intensity conditioning (RIC)
regimens for allogeneic stem cell transplantation. Un-
fortunately, the tradeoff for RIC has been an increase
in disease recurrence and a high incidence of chronic
graft-versus-host disease (cGVHD) with its consider-
able sequelae and ongoing risk for late transplantation-
related mortality (TRM) [1-3]. For the past decade, we
have used the reduced-intensity regimen of fludarabine
melphalan and alemtuzumab. It has a low rate of acuteniversity of Chicago, Section of Hematology/Oncology,
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cell depletion from alemtuzumab. It is well tolerated
and effective in patients with leukemia and lymphoma
entering transplantation with disease control, but has
shown disappointing results in those with more ad-
vanced disease [4-7].
Clofarabine is a novel nucleoside analog, which,
like other nucleoside analogs, requires intracellular
phosphorylation. Clofarabine’s triphosphate inhibits
DNA synthesis and repair [8,9]. Clofarabine also
directly induces apoptosis by activation of caspase 9
and by a direct interaction with the mitochondrial
membrane. It is the latter property that may explain
its superior activity in treating acute leukemia [10].
Clofarabine is indicated in the United States for the
treatment of pediatric patients (aged 1-21 years) with
relapsed or refractory acute lymphoblastic leukemia
(ALL) after at least two prior regimens at a recommen-
ded dose in monotherapy of 52 mg/m2 daily given over
2 hours for 5 days [11]. Hand-foot syndrome and usu-
ally reversible liver function abnormalities constitute
the dose-limiting toxicities (DLT) [12]. Clofarabine
also has activity in adult acute myelogenous leukemia913
914 Biol Blood Marrow Transplant 18:913-921, 2012K. van Besien et al.(AML), although it is not approved for this use. Previ-
ous adult AML studies used clofarabine 40 mg/m2
given over 1 hour and reported hepatic and skin toxic-
ities as being dose limiting [10]. More recently, clofar-
abine has also shown excellent activity in treating
patients with lymphoma, in which case much lower
doses are utilized [13]. Additionally, clofarabine has
been combined with intermediate-dose cytarabine
with promising results [14]. The combination with
high-dose cyclophosphamide may be synergistic, but
it was excessivelymyelosuppressive [15].We conducted
a phase I-II study of clofarabine, melphalan, and alem-
tuzumab for transplantation conditioning in patients
with high-risk hematologic malignancies, the results
of which are reported here. We conducted in parallel,
a study of clofarabine-bridging cytoreduction before
conditioning, reported elsewhere [16]. Only one pa-
tient who received clofarabine-bridge cytoreduction
was also enrolled in the protocol described here.PATIENTS AND METHODS
Eligibility
Eligibility was initially restricted to patients with
intermediate and high-risk disease features as per
American Society for Blood and Marrow Transplant
criteria [17]. This included the following: acute
leukemia beyond first remission, myelodysplastic syn-
dromes, recurrent or refractory lymphoma (including
Hodgkin lymphoma), chronic myelogenous leukemia
beyond first chronic phase, and other myeloprolifera-
tive disorders with poor prognostic features. Patients
with multiple myeloma or chronic lymphocytic leuke-
mia (CLL) and poor prognostic features were also el-
igible, but no patients with myeloma were enrolled.
As the study proceeded, several planned deviations
were allowed for patients in first complete response
who had high-risk disease by virtue of their karyotype
or molecular characteristics but who were felt not to be
appropriate candidates for standard myeloablative
conditioning.
Other eligibility criteria included a Zubrod perfor-
mance status #2,\75 years of age, adequate cardiac
and pulmonary involvement, calculated creatinine
clearance .50 mL/min, serum bilirubin\2.0 mg/dL,
and serum glutamic pyruvic transaminase\3  upper
limit of normal. Patients with evidence of chronic
active hepatitis or cirrhosis and those who were HIV
positive were excluded. Pregnancy was an exclusion.
Donors
HLA-compatible sibling or eight of eight HLA-
identical unrelated donors were used. One antigen-
mismatched related donors were acceptable.
High-resolution HLA typing was used throughout
this protocol. Donor peripheral blood stem cellswere the preferred source of hematopoietic stem cells
in all cases. Based on the donor’s preference, bone
marrow stem cells were used in a few recipients of un-
related donor stem cells.
Study Design
Phase I
For the phase I portion of the trial, we used an ac-
celerated titration design [18]. This has the advantage
of treating fewer patients at subtherapeutic levels than
the traditional ‘‘3 1 3’’ phase I design. Specifically, we
enrolled one patient per dose level, beginning at dose
level 1, until the first patient experienced a DLT or
two patients experienced a grade 3 drug-related toxic-
ity. At that point, we were to revert to a ‘‘31 3’’ design.
That is, two additional patients were to be accrued at
the dose that triggered the switch, and three to six pa-
tients were to be entered in that and each subsequent
cohort. All patients in each cohort were to be followed
for at least 28 days after transplantation before consid-
ering enrollment in a subsequent cohort. Under the
‘‘313’’ design, the maximally tolerated dose was de-
fined as the highest dose level producing no more
than one DLT in six patients.
Phase II
The primary endpoint for the phase II portion of
the trial was the progression-free survival rate (PFS)
at 1 year defined as the proportion of patients alive
and without evidence of recurrence 1 year after the ini-
tiation of therapy. We tested the null hypothesis that
the disease-free survival rate at 12 months is #25%
versus the alternative that it is at least 40%. These
boundaries were based on the 25% 1-year PFS previ-
ously observed with fludarabine-melphalan in high-
risk patients [3]. A Simon two-stage design was
employed in which 29 patients were enrolled in the
first stage [19]. Because the results in the first 29 pa-
tients were acceptable, an additional 43 patients were
enrolled for a total of 72. (Patients treated at the max-
imally tolerated dose during the phase I portion of the
study were included in the phase II trial.) If 22 or fewer
patients were progression free at 12 months, the regi-
men was to be rejected, whereas if 23 or more of the
total 72 patients ($32%) were progression free, the
regimen was to be considered worthy of further evalu-
ation in phase III trials. This design had an a-level of
10% and 90% power under the alternative hypothesis
that the true 12-month PFS rate was 40%. The prob-
ability of early termination for a true 12-month PFS
rate of 25% was 0.56.
Graft failure and liver toxicity weremonitored, and
early termination of the trial was to be considered if
there was evidence that the graft failure rate exceeded
10%or the rate of irreversible liver toxicity was.15%.
Chronic extensive GVHD over 40% would lead to
Biol Blood Marrow Transplant 18:913-921, 2012 915Clofarabine Melphalanconsideration for early stopping. Early stopping guide-
lines used a Pocock group sequential monitoring
boundary for a one-sided, overall a-level of 0.10 [20].
None of the early stopping guidelines were exceeded;
therefore, the trial continued to completion.
Conditioning Regimen and GVHD Prophylaxis
and Treatment
Alemtuzumabwas administered at 20mg i.v. on day
27 through day 23 over 1 hour. Clofarabine was ini-
tially administered i.v. over 1 hour on days27 through
23; subsequently, the protocol was amended to infuse
clofarabine over 3 hours. Melphalan was infused over
30 minutes on day 22 as previously described [4].
The doses of both clofarabine and melphalan were es-
calated as per the phase I design and are summarized
in Table 2. Body surface area calculations were based
on actual body weight. Tacrolimus i.v. was started on
day 22 and converted to oral dosing after neutrophil
engraftment as long as patients tolerated oral medica-
tions. Tacrolimus was adjusted to maintain levels of
5-15 ng/mL through day 100. Thereafter, tacrolimus
was tapered by 20% every week. In recipients of mis-
matched or unrelated donor transplantations, tacroli-
mus was continued until day 180. No other GVHD
prophylaxis was administered. First-line treatment for
acute GVHD (aGVHD) or chronic GVHD (cGVHD)
included steroids and resumption or continuation of
calcineurin inhibitors. Second-line treatment varied
and was often protocol driven.
Supportive Care
Patients were treated in rooms with high-
efficiency, particulate-free (HEPA) air filters and with
strict reverse isolation. They received filgrastim 5 mg/
kg/day subcutaneously, starting on day 1 after trans-
plantation until a neutrophil count of .10  109/L
had been reached. Infection prophylaxis, transfusion
support, and supportive care included high-dose acy-
clovir as well as pretransplantation trimethoprim/
sulfamethoxazole. Patients also received quinolone
prophylaxis until resolution of neutropenia and fluco-
nazole 200 mg/day (or another broad-spectrum: azole)
or echinocandin until day 180.Trimethoprim/sulfame-
thoxazole was given from engraftment until 1 year after
transplantation.
Patients who were cytomegalovirus (CMV) sero-
positive or had a CMV-seropositive donor were given
ganciclovir 5 mg/kg from day 28 until day 23. They
then were given acyclovir 10 mg/kg every 8 hours i.v.
until discharge. After engraftment, patients were con-
verted to valacyclovir 2,000 mg four times a day until
day 210 [21]. CMV negative donor/recipient pairs re-
ceived routine acyclovir prophylaxis. All patients were
screened weekly for CMV viremia until day 120 and
treated with ganciclovir or valganciclovir on detectionof CMV viremia. Irradiated and leuko-depleted blood
products were administered to maintain a hemoglobin
level greater than 8 g/dL and platelet count greater
than 10  109/L. There was no routine screening for
Epstein-Barr virus or adenovirus viremia.
Restaging and Outcome Definitions
Routine reevaluation was scheduled around day
28, day 100, day 180, and at the 1, 2, and 3 year anni-
versary and whenever warranted from signs or symp-
toms. The diagnosis of disease recurrence was based
on clinical and pathological criteria. The molecular
detection of minimal residual disease did not consti-
tute relapse or disease persistence. Chimerism assays
were performed at the same time points, using tech-
nology described elsewhere [22].
Toxicity was scored according to NCI/CTC ver-
sion 3 [23]. Any grade 5 (fatal) toxicity was considered
a DLT. In addition, grade 3 or 4 nonhematologic tox-
icities persisting for more than 24 hours was consid-
ered DLT with the exception of the following
expected toxicities: alopecia or anorexia, grade 4 nau-
sea, vomiting, diarrhea, or mucositis that resolved
(with or without supportive care) to less than grade 2
within 48 hours. Grade 4 hematologic toxicities were
not considered a DLT. Grade 4 or 5 infections and
toxicities associated with infection were not consid-
ered a DLT. Grade 3 or 4 elevation in hepatic trans-
aminases (alanine aminotransferase/serum glutamic
pyruvic transaminase and aspartate aminotransferase/
serum glutamic oxaloacetic transaminase) or alkaline
phosphatase that returned to \grade 2 elevation
within 14 days were anticipated and were not consid-
ered a DLT. Similarly, grade 4 elevations in amylase,
lipase, or total bilirubin that were asymptomatic and
that returned to less than grade 2 elevation within
7 days were not considered a DLT. For assessment
of direct organ toxicity, we focused on the time period
from the start of the conditioning regimen (day 27)
until 28 days after transplantation.
aGVHD was scored according to the criteria pro-
posed by Przepiorka et al [24]. cGVHDwas scored ac-
cording to the consensus criteria [25]. Engraftment
was defined as per International Bone Marrow Trans-
plant Registry and National Marrow Donor Program
guidelines [26].
Statistical Analysis
The results of the phase I study are reported using
descriptive statistics. Estimates of treatment-related
mortality (TRM), PFS, overall survival (OS), and re-
lapse rates refer to patients treated at phase II doses.
PFS (time to relapse or death as a result of any cause)
and OS were calculated using the Kaplan-Meier
product-limit estimate and expressed as probabilities
with a 95% confidence interval (CI) [27]. Cumulative
Table 1. Patient Characteristics
N 82
Age, median (range) 54 (21-73)
Gender: male/female 34/48
Diagnosis
ALL 3
AML 34
CLL 4
CML 3
Myelofibrosis 2
Lymphoma 27
MDS 9
ASBMT high/int/low 34/26/21
ECOG PS 0/1/2/missing 42/31/4/6
HCT CI $3 28 (33%)
Prior transplantation
Auto 7
Allo 6
MRD/MUD 42/40
Gender match 42
GFR mg/mL/1.73 m2 (range) 96 (25->120)
CML indicates chronic myeloid leukemia; ASBMT, American Society for
Blood and Marrow Transplant; MDS, myelodysplastic syndromes;
ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic
transplantation; MRD,matched related donor; MUD, matched unrelated
donor.
Figure 1. Patterns of decline in GFR in patients with renal toxicity.
Patients with grade 4-5 renal toxicity. Clo, day of administration of clo-
farabine; Mel, day of administration of melphalan; SCT, day of stem cell
transplantation. Alemtuzumab was given on the same days as clofara-
bine. Tacrolimus was started on day 2 after melphalan.
916 Biol Blood Marrow Transplant 18:913-921, 2012K. van Besien et al.incidence of disease progression with death before
progression as the competing risk and cumulative inci-
dence of TRM with relapse of the original disease as
the competing risk were also calculated. In order to
compare the cumulative incidence curves, we used
Gray’s test. Log-rank test was used to compare the
Kaplan-Meier curves. Cumulative incidence of
aGVHD and cGVHD were also calculated with death
or relapse as the competing risk.
Multivariate analyses used Cox proportional
hazards regressions for OS and PFS [28]. Regression
modeling for relapse and TRM incorporated compet-
ing risk [29]. For the multivariate models, independent
variables with P . .1 were excluded sequentially from
the models. Data were updated until June 30, 2011.RESULTS
Patient Characteristics
Eighty-two patients were enrolled. Ten patients re-
ceived the phase I doses of clofarabine and melphalan,
and 72were treated at phase II doses. Patient character-
istics are summarized in Table 1. Median age was 54
years, and approximately half of the donors were
unrelated. Forty-four AML or myelodysplastic syn-
drome patients, 27 lymphoma patients, five myelopro-
liferative disorder patients, four CLL patients, and
three patients with ALLwere enrolled. The largest sub-
group of 35 patients had American Society for Blood
andMarrowTransplant high-risk, active disease. Seven
had failed previous autologous transplantation. Five
had failed previous allogeneic transplantation; in all of
these, the same donor was used for the second
allogeneic transplantation. One had failed a priorsyngeneic transplantation and anHLA identical alloge-
neic sibling was used for the second transplantation.
Median serum creatinine on admission was 0.8 mg/dL
(range, 0.5-1.4), and the median estimated glomerular
filtration rate (GFR) on admission was 96 mL/min/
1.73m2 (range, 25-$120) based on the four variable
Modification of Diet in Renal Disease equation [30].
Engraftment and Chimerism
The first two patients had undergone a previous al-
logeneic transplantation. They recovered their counts
promptly after transplantation. Because they had re-
sidual donor chimerism at the time of conditioning
and the same donor was used for the second transplan-
tation, the impact of the regimen on donor engraft-
ment could not be assessed. All subsequent evaluable
patients at all dose levels engrafted, and there were
no cases of primary or secondary graft rejection. The
median time to neutrophil and platelet recovery was
10 days and 18 days, respectively. Only one patient
had neutrophil engraftment that was delayed beyond
day 28. She was reconditioned but recovered cell
counts with full-donor chimerism before the second
stem cell infusion. Chimerism studies showed that all
but one patient achieved full-donor chimerism in un-
sorted cells, and 84% achieved full-donor chimerism
in T cells at day 30. Donor chimerism slowly declined
over time, so that by day 180, only approximately
half of the patients were full-donor chimeras
(Figure 1). Such mixed chimerism is common after
alemtuzumab-based conditioning, and in our experi-
ence is protective of GVHD but does not predict for
disease recurrence [22]. Clofarabine at phase II dose
levels appears to be more immunosuppressive than flu-
darabine, based on higher levels of donor chimerism,
achieving statistical significance by day 180.
GVHD
The cumulative incidence of aGVHD grade II-IV
was 22% (95% CI, 15-29). The cumulative incidence
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Biol Blood Marrow Transplant 18:913-921, 2012 917Clofarabine Melphalanof grade III-IV aGVHD was 5% (95% CI, 1-9). The
incidence of aGVHD was similar among related and
unrelated donor recipients. The cumulative incidence
of cGVHD was 5% (95% CI, 2-8), all cases occurring
in unrelated donor recipients.
Toxicity (Table 2)
Phase I study
Three nonrelapse deaths occurred during the
phase I portion of the study because of sepsis (n 5 2)
and a cardiac event in a patient with coronary artery
disease (n 5 1). The latter patient had a history of
breast cancer and had undergone multiple prior che-
motherapy regimens as well as chest wall irradiation
resulting in therapy-related AML. On autopsy, there
was advanced coronary stenosis and an incidental find-
ing of residual breast cancer. None of the three deaths
was attributed to the conditioning regimen, and these
patients were replaced.
Table 2 details the number of patients per dose
level and the toxicities observed. Except for transient
liver function abnormalities and occasional cases of
skin toxicity, no grade 3-5 toxicities occurred during
the phase I portion of the study that were attributed
to the conditioning regimen. Six patients were
enrolled at the final dose level of clofarabine 40 mg/
m2  5 and melphalan 140 mg/m2  1, and no
DLTs were observed. This dose level combines the
recommended dose of clofarabine in adults with a com-
monly used transplantation dose of melphalan and was
adopted for further phase II study.
Phase II study
Twenty-four patients were treated at the initial
phase II level (clofarabine 40 mg/m2  5 and melpha-
lan 140 mg/m2). Grade 3-5 renal toxicity was observed
in five of them. Overall, grade 3-5 renal toxicity was
observed in 16 of 74 patients (21%) treated at the phase
II doses. Sepsis was associated in only two of these
cases. Grade 1-2 elevations of creatinine were observed
in another 20 patients. Grade 2-5 renal failure was of-
ten irreversible. Figure 2 shows the rate of decline of
GFR in the patients with grade 4-5 toxicity. The two
patients with concomitant sepsis are excluded from
this figure. In the majority of cases, the onset of decline
in GFR occurred within days of the start of condition-
ing. There was a significant correlation between age
and the occurrence of renal toxicity (r 5 .26, P 5
.018) and between baseline GFR and occurrence of re-
nal toxicity. As expected, increasing age and lower
baseline GFR were themselves highly correlated.
Transient liver function abnormalities were com-
mon and occasionally reached CTC level 3 or 4, but
they were always rapidly reversible. No cases of sinu-
soidal obstruction disease/veno-occlusion disease
were observed. Seven cases of grade 3 hand-foot
Figure 2. (A) PFS and (B) OS.
Table 3. Multivariate Analysis of OS, PFS, TRM, and Relapse
918 Biol Blood Marrow Transplant 18:913-921, 2012K. van Besien et al.syndrome were observed, six of which were at the
40 mg/m2 level.
Other toxicities are also documented in Table 2
and were uncommon. Of note, we did observe four
cases of severe and prolonged mental status changes,
which in one case was irreversible. There were also
three cases of very early fatal heart failure during the
phase II study. A 67-year-old patient undergoing sec-
ond allogeneic transplantation developed pneumonia
and intractable arrhythmias and died on day 15. A
51-year-old AML patient with preexisting cardiomy-
opathy died on day 21 from a combination of renal
failure and chronic heart failure. A similar event oc-
curred in a 61-year-old female with AML, diabetes,
hypertension, and obesity, who died on day 11.Based on Pretransplantation Characteristics
Variables Relative Risk P Value
OS
ASBMT risk group 0.59 .015
Age 2.6 .004
PFS
ASBMT risk group 0.59 .01
TRM
Age 0.17 .002
Relapse
Age 5 .003
ASBMT indicates American Society for Bone Marrow Transplant.OS, PFS, TRM, and Relapse (Table 3)
With a median follow-up of 25 months (range,
3-43 months), 27 patients treated at phase II levels
remain alive and free of disease. In addition, two par-
ticipants in the phase I part of the study remain alive
and free of recurrence after 44 and 49 months.
In the phase II study, the cumulative incidence of
TRM was 19% (95% CI, 10-28) at 100 days and
26% (95% CI, 16-36) at 1 year. Cumulative incidenceof relapse was 29% (95% CI, 18-40) at 1 year. OS was
80% (95% CI, 71-89) at 100 days and 59% (95% CI,
47-71) at 1 year. PFS was 60% (95% CI, 48-72) at
100 days and 45% (95%CI, 33-67) at 1 year (Figure 2).
In multivariate analysis, age .55 years predicted
for an increased risk of TRM as well as a decreased
risk for disease relapse (Table 3). Age .55 years and
disease risk category were the determinants of survival.
Disease risk category was the only significant predictor
of PFS.
We also analyzed an alternative model that incor-
porated the GFR on the day of transplantation. AGFR
of\80 mL/min/1.73 m2 on the day of transplantation
reflected an early decline in GFR and was by far the
best predictor of TRM, survival, and relapse. Those
with a GFR \80 mL/min/1.73 m2 had a 19-fold
increase in TRM and corresponding decreases in OS
and PFS. Early renal impairment was therefore the
major determinant of long-term outcome.DISCUSSION
Allogeneic transplantation remains the most effec-
tive treatment in many cases of hematologic malig-
nancy but is beset by a high incidence of disease
recurrence and toxicity. Efforts at reducing toxicity
by the use of RIC and/or alemtuzumab have been
successful in patients with chemotherapy-responsive
disease, but high relapse rates remain a major obstacle
for patients with more advanced disease.With the pur-
pose of improving outcomes in patients with advanced
hematologic malignancies, we replaced fludarabine in
our conditioning regimen with clofarabine, a novel
nucleoside analog with better activity in leukemia
and lymphoma. At the time of this study’s design, we
were aware of pharmacodynamic studies showing
that higher doses of clofarabine were associated with
more sustained inhibition of replication of leukemic
blasts and better accumulation of clofarabine triphos-
phate in CLL cells [31].
The phase I portion showed that 40 mg/m2 for 5
days and melphalan 140 mg/m2 was a tolerable dose
with the primary toxicity of reversible transaminitis.
The completion of the phase II study allowed us to
Biol Blood Marrow Transplant 18:913-921, 2012 919Clofarabine Melphalanestablish estimates of the immunosuppressive poten-
tial, efficacy, and toxicity of this regimen. Engraftment
occurred promptly with durable engraftment in all
evaluable patients. We therefore established in agree-
ment with others’ observations that clofarabine has im-
munosuppressive properties that are equal or superior
to those of fludarabine [32].
The regimen met the phase II primary endpoint of
PFS of 32%ormore, as 28 (39%) patients have survived
free of disease formore than a year after transplantation,
and the estimated 1-year PFS is 45%.We therefore be-
lieve the regimen warrants additional study. The 1-year
PFS of 31% for patients with active disease is similar to
the 25%PFSwe previously reported for similar patients
treated with fludarabine-melphalan-alemtuzumab [4].
However, only one out of seven patients with active dis-
ease has relapsed beyond 1 year, and six of 35 high-risk
patients remain in remission with a median follow-up
of 2 years (range, 1.2-3.0 years). By contrast with fludar-
abine melphalan high risk patients continued to relapse
beyond one year and there were very few with durable
remissions. These data suggest that clofarabine-
alkylator combinations may have greater antileukemic
activity and result in better long-term disease control.
Other studies provide additional support for high activ-
ity of clofarabine alklaytor combinations. Farag et al.
[32] used busulfan and clofarabine in 15 patients, mostly
with refractorydisease and found that sevenpatients sur-
vived in remission for longer than 1 year. Mineishi et al.
[33] treated 46 patients with busulfan and clofarabine,
none of them in remission. In this study, 94% of AML
patients achieved remission, and the median 18-month
survival for AML patients was 50%. Andersson et al.
[34] report on 51 patientswithAMLor chronicmyeloid
leukemia, many with refractory disease who underwent
conditioningwith a combinationofbusulfan clofarabine
and varying doses of fludarabine. Seventeen of 32 pa-
tients with active leukemia were in remission with me-
dian follow-up of 14 months. Similar outcomes were
described in other preliminary reports including
some pediatric studies [35-38]. Whether busulfan,
melphalan, or total-body irridiation are better for com-
bination with clofarabine requires further study, as do
the relative benefits and disadvantages of in vivo T cell
depletion [39,40].
Although efficacy and long-termPFSwere promis-
ing, unexpected acute renal toxicity affected long-term
outcomes. Renal toxicity occurred early and predicted
for TRM and survival. This prompted us to reduce the
dose of clofarabine to 30 mg/m2, and subsequently,
based on pediatric data, to lengthen the infusion time
of clofarabine. These modifications did not appear to
reduce renal toxicity. Recipient age and baseline GFR
were the only parameters that correlatedwith renal tox-
icity, and they may be surrogates for each other.
Our data on renal injury contrast with other
transplantation reports. Kirshbaum et al. [32] in a studyof 16 patients combined clofarabine with melphalan,
and Farag et al. [38] combined it with busulfan in a 15-
patient study.Each reportedonlyonecaseof irreversible
renal toxicity. Others have not reported any evidence of
renal toxicity [33,34], and we cannot completely explain
this discrepancy between studies. It is of course possible
that the limited number of patients in someother studies
and in the phase I part of our own study precluded
detection of renal toxicity. It is unlikely that our policy
of pretransplantation administraton of ganciclovir,
trimethoprim/sulfamethoxazole, and an oral quinolone
should be implicated as a cause of renal failure because
it has been used as a standard in all our protocols, and
we have not observed similar deteriorations in
previous studies [4,41]. Neither melphalan nor
alemtuzumab are associated with nephrotoxicity and
both can even be safely administered to patients with
renal failure [42]. Furthermore, fludarabine, melphalan,
and alemtuzumab or fludarabine, busulfan, and alemtu-
zumab combinations rarely invoke early renal injury
[4,41]. Renal deterioration, often occurred early, after
one or two doses of clofarabine and alemtuzumab but
before administration of melphalan, tacrolimus, or
other renal-damaging drugs. Unless one believes there
is a hitherto unknown interaction between clofarabine
and alemtuzumab, our findings suggest that clofarabine
has intrinsic nephrotoxicity, at least in susceptible pa-
tients. Patients with impaired baseline renal function
and/or older adults may be particularly prone to it.
Our data are consistent with those of Faderl et al. [43],
who in a study of elderly adults with leukemia observed
elevations in creatinine in up to 36% of patients who re-
ceived clofarabine 30 mg/m2 5 days, all in the setting
of serious adverse events and hypotension.
In addition to renal toxicity, there were also four
cases of early fatal shock, includingoneduring thephase
I portion of the study. These events tended to occur
during or immediately after completion of condition-
ing. They are reminiscent of a syndrome of a cytokine
release event originally described by Jeha and are asso-
ciatedwithhypotension, respiratory distress, andmulti-
organ failure [44]. We cannot therefore rule out that
clofarabine contributed to these events, but high-dose
melphalan, particularly in combination with nucleoside
analogs [45,46], and even rarely alemtuzumab [47], have
also been associatedwith rare cases of fulminant cardiac
failure.
The only other unexpected toxicity was encepha-
lopathy, which occurred in four patients and was irre-
versible in one. Nucleoside analogs, and in particular
fludarabine, have been associated with encephalopathy
[48]. Other causes of neurologic toxicity including
toxicity from calcineurin inhibitors, antivirals, or anti-
fungals, however, cannot be excluded.
In contrast to the severity of renal problems,
liver function abnormalities were always rapidly
reversible, and no cases of sinusoidal obstruction
920 Biol Blood Marrow Transplant 18:913-921, 2012K. van Besien et al.syndrome/veno-occlusive disease were observed
throughout the courseof this study.No fatal or irrevers-
ible hepatic toxicity was observed with our clofarabine-
melphalan combination in contrast to the studies of clo-
farabine and busulfan where occasional cases occurred
[32-34]. The hepatic toxicity of clofarabine therefore
is of limited consequence, at least in the regimen
studied. Hand-foot syndrome occurred but was not
dose limiting. The only study in which clofarabine
hand-foot syndrome appeared limitingwas in combina-
tion with cytarabine, a known skin toxin [49].
In summary, our phase II trial yielded promising
PFS, and further investigaton of clofarabine-
melphalan combinations is warranted. However, we
newly identified renal toxicity as a considerable risk,
particularly in older patients. Ongoing pharmacoki-
netic analysis will help better characterize this toxicity
and to design future studies that mitigate renal toxicity,
potentially by reducing or individualizing clofarabine
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